Last reviewed · How we verify
Rivoceranib (Apatinib)
Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2).
Rivoceranib (Apatinib), a small molecule VEGFR-2 inhibitor, is under development by Jiangsu HengRui Medicine for various cancers, including hepatocellular carcinoma and gastric cancer. It is being evaluated in multiple Phase 2 and 3 trials, showing promise as an adjuvant therapy and in combination with other treatments.
At a glance
| Generic name | Rivoceranib (Apatinib) |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting VEGFR2, Rivoceranib reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating various types of cancer.
Approved indications
- Metastatic gastric cancer, Metastatic non-small cell lung cancer
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Vomiting